RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H1 2018

  • ID: 4537865
  • Report
  • 63 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • ArQule Inc
  • AstraZeneca Plc
  • Bayer AG
  • Merck & Co Inc
  • Novartis AG
  • MORE
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H1 2018

Summary:

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - RAC-beta serine/threonine-protein kinase is an enzyme encoded by the AKT2 gene. It plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2.

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 6, 1 and 1 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Hematological Disorders, Non Malignant Disorders and Other Diseases which include indications Endometrial Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Fallopian Tube Cancer, Metastatic Breast Cancer, Peritoneal Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Small-Cell Lung Cancer, Adenoid Cystic Carcinoma (ACC), Anal Cancer, Brain Cancer, Congenital Vascular Malformation, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Leukemias, Lymphoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Hamartoma Syndrome, Neuroendocrine Cancer, Orphan Diseases, Pancreatic Cancer, Proteus Syndrome, Renal Cell Carcinoma, Sickle Cell Disease, Solid Tumor and Thymoma (Thymic Epithelial Tumor).

The latest report RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H1 2018, outlays comprehensive information on the RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)
  • The report reviews RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ArQule Inc
  • AstraZeneca Plc
  • Bayer AG
  • Merck & Co Inc
  • Novartis AG
  • MORE
Introduction

Report Coverage

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Overview

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

ArQule Inc

AstraZeneca Plc

Bayer AG

Cotinga Pharmaceuticals Inc

Merck & Co Inc

Novartis AG

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Drug Profiles

AZD-5363 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1125976 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COTI-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

miransertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-2206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-2206 + selumetinib sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trametinib dimethyl sulfoxide + uprosertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

uprosertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Dormant Products

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Apr 03, 2018: Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Mar 20, 2018: Cotinga Pharmaceuticals Provides Update on COTI-2 Clinical Programs

Mar 15, 2018: ArQule to Present Data on miransertib at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Jan 25, 2018: Cotinga Pharmaceuticals Announces Publication of Positive Data from Preclinical Study of COTI-2 in PLOS One

Dec 19, 2017: Critical Outcome Technologies Announces Pharmacodynamic Data and Positive Signals of Efficacy from Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies

Nov 15, 2017: Critical Outcome Technologies Announces Pharmacokinetic Data From Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies

Nov 01, 2017: FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome

Oct 11, 2017: Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma

Aug 14, 2017: Critical Outcome Technologies Completes Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies

Jun 07, 2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases

May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting

Jan 10, 2017: Critical Outcome Advances to Fourth Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers

Dec 03, 2016: Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting

Jul 12, 2016: Critical Outcome Initiates Third Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers

Jun 06, 2016: Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by ArQule Inc, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Bayer AG, H1 2018

Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Pipeline by Novartis AG, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Route of Administration, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ArQule Inc
  • AstraZeneca Plc
  • Bayer AG
  • Cotinga Pharmaceuticals Inc
  • Merck & Co Inc
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll